19023-94-0

Usage

Uses

Used in Pharmaceutical Industry:
Cbz-N-Methylethylenediamine is used as a building block for the synthesis of various pharmaceuticals, leveraging its capacity to be modified into multiple functional groups. This makes it instrumental in the development of a wide array of biologically active compounds, including antifungal agents and antiviral drugs.
Used in Agrochemical Industry:
In the agrochemical sector, Cbz-N-Methylethylenediamine serves a similar role as in pharmaceuticals, acting as a key intermediate in the synthesis of compounds designed to protect crops and enhance agricultural productivity. Its versatility in creating functional groups is crucial for developing new and effective agrochemical products.
Storage and Handling:
Cbz-N-Methylethylenediamine must be handled and stored with care to ensure safety and stability. It should be kept in a dry, well-ventilated area and separated from incompatible materials and sources of ignition to prevent any potential hazards.

InChI:InChI=1/C11H16N2O2/c1-12-7-8-13-11(14)15-9-10-5-3-2-4-6-10/h2-6,12H,7-9H2,1H3,(H,13,14)

Upstream product

• 56221-05-7 N-Benzyliden-N'-methylethylendiamin 
• 501-53-1 benzyl chloroformate 
• 109-81-9 N-methyl-ethane-1,2-diamine 
• 75315-63-8 N-(benzyloxycarbonyl)succinimide 
• 1221593-52-7 methyl-[2-(2,2,2-trifluoro-acetylamino)-ethyl]carbamic acid benzyl ester 
• 40052-13-9 mono-tert-butyl malonate 

Downstream Products

• 1276121-44-8 [2-(benzyloxycarbonyl-methyl-amino)-ethyl]-dicarbamic acid tert-butyl ester 
• 1048360-18-4 {(S)-4-({amino-[(E)-2,2,4,6,7-pentamethyl-2,3-dihydro-benzofuran-5-sulfonylimino]-methyl}-amino)-1-[2-(benzyloxycarbonyl-methyl-amino)-ethyl carbamoyl]-butyl}-carbamic acid tert-butyl ester 
• 1221593-56-1 {(S)-5-acetylamino-5-[2-(benzyloxycarbonyl-methyl-amino)-ethyl carbamoyl]-pentyl}-carbamic acid isopropyl ester 
• 1221593-55-0 {(S)-5-amino-5-[2-(benzyloxycarbonyl-methyl-amino)-ethylcarbamoyl]-pentyl}-carbamic acid tert-butyl ester 
• 1221593-54-9 {(S)-1-[2-(benzyloxycarbonyl-methyl-amino)-ethylcarbamoyl]-5-tert-butoxycarbonylamino-pentyl}-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 533923-22-7 C₅₅H₆₅F₃N₆O₂₁ 
• 533923-27-2 C₄₆H₆₂N₆O₁₉ 
• 959154-70-2 C₃₂H₅₂N₆O₉ 

Relevant academic research and scientific papers

Pharmaceutical compositions with attenuated release of phenolic opioids

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with th

An enzyme and its optional [...] modified ketone and inhibitor composition comprising (by machine translation)

PROBLEM TO BE SOLVED: ketone-containing acrylic misuse, abuse or overload is prevented for a new takable amt. provitamin drag pain. SOLUTION: a compound represented by the following formula is represented, in which the drag oxystyrene provitamin hydrocodone ketone-containing acrylic. Pre-selected drug profile is modified and the ketone and schisandrin [...] holding hung contg. compsn. method for administration to a patient. Selected drawing: no (by machine translation)

COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS

The present disclosure provides a composition comprising a GABAA agonist and a GI enzyme inhibitor. The present disclosure also provides a composition comprising (a) a GI enzyme inhibitor and (b) a first drug that interacts with a second drug to produce an adverse effect when the second drug is co-ingested as a GI enzyme-cleavable prodrug with the first drug. Such an interaction can be additive or synergistic.

COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF

The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.

Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenol-modified opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the phenol-modified opioid prodrug so as to modify enzymatic cleavage of the phenol-modified opioid prodrug.

Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias

Chromophore modification of the anthracenediones related to mitoxantrone in an attempt to provide agents with diminished or no cardiotoxicity has resulted in a novel class of DNA binders, the anthrapyrazoles. Their synthesis was carried out by a two-stage